- Conditions
- Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- durvalumab, carboplatin AUC 2/paclitaxel, External beam radiation (EBRT), esophagogastrectomy, Tremelimumab
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 539
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- RAI1 Gene 17P11.2 Deletion+Duplication
- Interventions
- Electroencephalography/Polysomnography (EEG/PSG), Skin Biopsy, Blood draw
- Diagnostic Test · Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Month to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- Lymph node template, Transverse versus vertical closure, antibiotic prophylaxis, Hemostatic Agent
- Procedure · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 3,204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Montvale, New Jersey • Harrison, New York + 2 more
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
- Interventions
- therapeutic autologous lymphocytes, cyclophosphamide, aldesleukin, polymerase chain reaction, gene rearrangement analysis, lymph node biopsy, genetically engineered lymphocyte therapy, bone marrow aspiration, flow cytometry, laboratory biomarker analysis, enzyme-linked immunosorbent assay
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Blood Brain Barrier Defect
- Interventions
- Regadenoson, Temozolomide, Microdialysis catheter
- Drug · Device
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Cancer, Early-Onset
- Interventions
- Neoadjuvant chemotherapy administered before surgical extraction of a tumor, Observational
- Drug · Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 12
- States / cities
- Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 7 more
- Conditions
- Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7, Stage IVA Vulvar Cancer AJCC v7, Vulvar Squamous Cell Carcinoma
- Interventions
- Cisplatin, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Therapeutic Conventional Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 193
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Burbank, California + 130 more
- Conditions
- Ovarian Cancer
- Interventions
- PDS (Primary Debulkdung Surgery), 6 cycles of standard chemotherapy, Timing of surgery after 3 cycles of standard NACT, IDS, IDS, 3 cycles of standard chemotherapy
- Procedure · Drug
- Lead sponsor
- AGO Study Group
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 797 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colorectal Lesion, Colorectal Adenoma, Colorectal Polyp, Rectal Lesion, Rectal Adenoma, Rectal Polyp, Sigmoid; Lesion, Sigmoid Colon Polyp
- Interventions
- Endoscopic submucosal dissection using the ELS System
- Device
- Lead sponsor
- EndoQuest Robotics, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Orlando, Florida • Boston, Massachusetts + 2 more
- Conditions
- End Stage Renal Disease, Antibody Mediated Rejection
- Interventions
- Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
- Drug · Procedure
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Stomach Cancer, Gastric Cancer
- Interventions
- 5-Fluorouracil, Folinic Acid, Oxaliplatin, Radiotherapy, Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Cancers, Leukemia
- Interventions
- Leukapheresis, Fludarabine, Cyclophosphamide, T-cell Infusion
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
- Interventions
- Encorafenib Pill, Binimetinib Pill, Nivolumab
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Pancreatic Cancer
- Interventions
- Neoadjuvant capecitabine, panitumumab and radiation
- Other
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Melanoma
- Interventions
- Fianlimab, Cemiplimab, Pembrolizumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 28
- States / cities
- La Jolla, California • San Francisco, California • Santa Monica, California + 21 more
- Conditions
- Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
- Interventions
- Pazopanib Hydrochloride, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Pharmacological Study, Laboratory Biomarker Analysis
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Colorectal Cancer
- Interventions
- Not listed
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, bb2121, Cyclophosphamide, Fludarabine, leukapheresis
- Drug · Biological · Procedure
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 15
- States / cities
- Duarte, California • Palo Alto, California • San Francisco, California + 11 more
- Conditions
- Rectal Cancer, Low Anterior Resection
- Interventions
- Stoma reversal
- Procedure
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete DiGeorge Syndrome
- Interventions
- Thymus Tissue for Transplantation
- Biological
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Advanced Stage Head and Neck Cancer
- Interventions
- Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS, Embryonal Tumor With Multilayered Rosettes, Pineoblastoma, Embryonal Brain Tumor Not Otherwise Specified, Ependymoma
- Interventions
- Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA), Group A Standard-of-Care Backbone Therapy, Group B Salvage Backbone Therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Bladder Cancer
- Interventions
- SUTENT, Placebo
- Drug · Other
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 5 more
- Conditions
- Breast Cancer, Cancer of Breast, Cancer of the Breast, Melanoma, Malignant Melanoma
- Interventions
- Sentinel lymph node biopsy, Goggle-based device with light-emitting diodes (LED), Indocynanine Green
- Procedure · Device · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri